Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
Provided By PR Newswire
Last update: Aug 6, 2024
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile --
Read more at prnewswire.com
